logo
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

Business Wire13-05-2025

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for the first quarter ended March 31, 2025.
'In the first quarter of 2025, we continued to make progress with our pipeline programs by exercising our option early to license VS-7375 from our partner GenFleet Therapeutics, completing enrollment in the initial cohorts in our RAMP 205 clinical trial in first-line metastatic pancreatic cancer, and continuing enrollment in the triplet combination in our RAMP 203 clinical trial in advanced KRAS G12C mutant non-small cell lung cancer,' said Dan Paterson, president and chief executive officer of Verastem Oncology. 'With a strengthened financial position, we are looking forward to a transformational second quarter with the FDA approval and launch of AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer, our plans to initiate a Phase 1/2a study in the U.S. for VS-7375, our potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, in mid-2025, and share updated data for both VS-7375 and RAMP 205 at ASCO.'
First Quarter 2025 and Recent Updates
Avutometinib and Defactinib Combination in Low-Grade Serous Ovarian Cancer (LGSOC)
Announced the U.S. Food and Drug Administration (FDA) approved AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent LGSOC who have received prior systemic therapy on May 8, 2025, in advance of PDUFA action date of June 30, 2025.
Initiation of the commercial execution of the AVMAPKI FAKZYNJA CO-PACK launch in the U.S.
AVMAPKI FAKZYNJA CO-PACK is now available through a specialty distribution network in the U.S.
A support program for patients prescribed AVMAPKI FAKZYNJA CO-PACK, called Verastem Cares™, is now available.
Submitted request for NCCN guideline inclusion.
Shared multiple oral and poster presentations at the American Association of Cancer Research (AACR) Annual Meeting 2025 on April 25-30, highlighting the exploration of the mechanisms by which the Company's FAK inhibitor increases the anti-tumor efficacy of avutometinib.
Multiple abstracts were selected for oral and poster presentations at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women's Cancer on March 14-17 in Seattle. These presentations included an oral presentation of additional analyses from the Phase 2 RAMP 201 trial of avutometinib and defactinib combination with recurrent LGSOC and an oral presentation of interim results from a Phase 2 Investigator-Sponsored Trial evaluating avutometinib plus defactinib in advanced or recurrent gynecologic mesonephric cancer.
Key Milestones Expected for 2025:
Primary analysis from both the FRAME and RAMP 201 clinical trials anticipated to be published in H1 2025.
Complete enrollment for the international Phase 3 confirmatory RAMP 301 clinical trial for patients with recurrent LGSOC regardless of KRAS mutation status by the end of 2025.
Report initial data from the RAMP 201J Phase 2 clinical trial being conducted in Japan with JGOG in H2 2025.
Continue to advance the regulatory pathway in Japan and Europe.
RAMP 205: Avutometinib Plus Defactinib in Combination with Chemotherapy in First-Line Metastatic Pancreatic Cancer
Completed enrollment of 60 patients in the dose-level evaluation phase of RAMP 205 study in Q1; follow-up continues.
In March 2025, announced several updates to the trial, including the addition of a new dose level '0' to evaluate the doses of avutometinib and defactinib used in LGSOC and expanding all dose levels to 12 patients each, including six additional patients to dose level '1', where 5/6 patients reported an objective response (83% cORR) at the ASCO 2024 annual meeting.
Key Milestones Expected for 2025:
Plan to report additional data when ASCO abstracts are live on May 22, 2025.
Select the recommended Phase 2 Dose (RP2D) for trial expansion in H1 2025.
RAMP 203: Avutometinib Plus Defactinib in Combination with a KRAS G12C Inhibitor in Non-Small Cell Lung Cancer (NSCLC)
Completed enrollment in the KRAS G12C inhibitor prior-treated Stage 1 Part B doublet cohort in Q1 2025.
Completed enrollment in the planned dose level evaluation cohorts for the triplet combination in Q1 2025.
Key Milestones Expected for 2025:
Present an interim update of both doublet and triplet data at a medical meeting in H2 2025.
VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Advanced Solid Tumors
Verastem announced in April 2025 that the FDA had cleared the Company's Investigational New Drug (IND) application for VS-7375, enabling a Phase 1/2a trial in advanced solid tumors in the U.S.
Shared a presentation at the AACR Annual Meeting 2025, highlighting that VS-7375 was found to be more potent than other KRAS G12D inhibitors in preclinical models.
GenFleet announced on Feb. 28, 2025, that it had dosed the first patient in the Phase 2 portion of the trial in China.
Verastem announced on January 14, 2025, that it had exercised its option early to license GFH375 (VS-7375) from partner GenFleet Therapeutics. In addition, the Company announced preliminary clinical data from the Phase 1 dose-escalation study conducted by GenFleet in China. In the study, VS-7375 demonstrated oral bioavailability, with no DLTs across six dose levels, and partial responses were achieved among multiple patients with both pancreatic and lung cancers.
Key Milestones Expected for 2025:
Initiate a Phase 1/2a trial in the U.S. by mid-2025.
GenFleet to share clinical data from the Phase 1 study of VS-7375 in an oral presentation at ASCO on Monday, June 2, 2025.
Upcoming Presentations
ASCO Annual Meeting
The meeting will be held from May 30 to June 3, 2025, in Chicago, IL, and abstracts are under embargo until May 22, 2025, at 5:00 pm EDT.
Title: A First-in-Human Phase I/II Study of GFH375, a Highly Selective and Potent Oral KRAS G12D Inhibitor in Patients with KRAS G12D Mutant Advanced Solid Tumors
Abstract Number: 3013
Session: Rapid Oral Abstract Sessions: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Date/Time: Monday, June 2, 2025 from 8:00 am to 9:30 am CDT
Title: Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Updated safety and efficacy of a phase 1b/2 study (RAMP 205)
Abstract Number: e16043
Accepted for inclusion in the 2025 ASCO Annual Meeting Proceedings, Journal of Clinical Oncology supplement. The abstract is under embargo until May 22, and the Company will be reporting additional data then.
ESMO Gynaecological Cancers Congress 2025
The meeting will be held from June 19 to 21, 2025, in Vienna, Austria, and the abstract is under embargo until June 16, 2025.
Title: Blood ctDNA vs tumor tissue screening for the detection of KRAS mutations in low-grade serous ovarian cancer
Abstract Number: 276
Date/Time: Thursday, June 19, from 2:00 to 3:30 pm EDT
Corporate Updates
In April 2025, Verastem strengthened its balance sheet by raising gross proceeds of approximately $75 million in a private placement of 3.4 million shares of its common stock and 7.3 million pre-funded warrants to purchase 7.3 million shares of its common stock.
First Quarter 2025 Financial Results
Verastem Oncology ended the first quarter of 2025 with cash, cash equivalents and investments of $117.6 million. On a pro forma basis, taking into account the $75 million of gross proceeds raised in a private placement in April, cash and cash equivalents were $192.6 million as of March 31, 2025.
Total operating expenses for the three months ended March 31, 2025 (the '2025 Quarter') were $44.2 million, inclusive of $6.8 million of one-time charges, compared to $28.1 million for the three months ended March 31, 2024 (the '2024 Quarter').
Research & development expenses for the 2025 Quarter were $29.2 million, compared to $17.7 million for the 2024 Quarter. The increase of $11.5 million, or 65.0%, was primarily related to the option exercise fee related to the GenFleet G12D program, increased contract research organization costs, and increased drug substance and drug product costs.
Selling, general & administrative expenses for the 2025 Quarter were $15.0 million, compared to $10.4 million for the 2024 Quarter. The increase of $4.6 million, or 44.2%, was primarily related to additional costs in anticipation of a potential launch of avutometinib and defactinib in KRAS mt LGSOC, increased personnel costs, including non-cash stock compensation, and one-time financing costs associated with the note purchase agreement.
Net loss for the 2025 Quarter was $52.1 million, or $0.96 per share (basic and diluted), compared to $33.9 million, or $1.26 per share for the 2024 Quarter.
For the 2025 Quarter, non-GAAP adjusted net loss was $42.9 million, or $0.79 per share (diluted) compared to non-GAAP adjusted net loss of $26.2 million, or $0.98 per share (diluted), for the 2024 Quarter. Please refer to the GAAP to non-GAAP Reconciliation attached to this press release.
Use of Non-GAAP Financial Measures
To supplement Verastem Oncology's condensed consolidated financial statements, which are prepared and presented in accordance with generally accepted accounting principles in the United States (GAAP), the Company uses the following non-GAAP financial measures in this press release: non-GAAP adjusted net loss and non-GAAP net loss per share. These non-GAAP financial measures exclude certain amounts or expenses from the corresponding financial measures determined in accordance with GAAP. Management believes this non-GAAP information is useful for investors, taken in conjunction with the Company's GAAP financial statements, because it provides greater transparency and period-over- period comparability with respect to the Company's operating performance and can enhance investors' ability to identify operating trends in the Company's business. Management uses these measures, among other factors, to assess and analyze operational results and trends and to make financial and operational decisions. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the Company's operating results as reported under GAAP, not in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. In addition, these non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. The determination of the amounts that are excluded from non-GAAP financial measures is a matter of management judgment and depends upon, among other factors, the nature of the underlying expense or income amounts. Reconciliations between these non-GAAP financial measures and the most comparable GAAP financial measures for the three months ended March 31, 2025 and 2024 are included in the tables accompanying this press release after the unaudited condensed consolidated financial statements.
About AVMAPKI and FAKZYNJA Combination Therapy
AVMAPKI (avutometinib) inhibits MEK kinase activity while also blocking the compensatory reactivation of MEK by upstream RAF. RAF and MEK proteins are regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. Blocking RAF and/or MEK activates FAK, a key mediator of drug resistance. FAKZYNJA (defactinib) is a FAK inhibitor and together, the avutometinib and defactinib combination was designed to provide a more complete blockade of the signaling that drives the growth and drug resistance of RAS/MAPK pathway-dependent tumors.
The U.S. Food and Drug Administration (FDA) approved AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent LGSOC who have received prior systemic therapy on May 8, 2025. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Verastem is also evaluating avutometinib in combination with defactinib and other agents as a potential treatment for patients with advanced pancreatic cancer (RAMP 205; NCT05669482) and advanced KRAS G12C mutant non-small cell lung cancer (RAMP 203; NCT05074810). Avutometinib and defactinib are not approved by the FDA or any other regulatory authority, either in combination or with other therapies, for any of these investigative uses. Neither avutometinib nor defactinib are approved by the FDA or any other regulatory authority on a stand-alone basis for any use.
AVMAPKI FAKZYNJA CO-PACK U.S. Indication
Indication
AVMAPKI FAKZYNJA CO-PACK is indicated for the treatment of adult patients with KRAS -mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Important Safety Information
Warnings and Precautions
Ocular Toxicities: Ocular toxicities, including visual impairment and vitreoretinal disorders, occurred. Perform comprehensive ophthalmic evaluation at baseline, prior to cycle 2, every three cycles thereafter, and as clinically indicated. Withhold AVMAPKI FAKZYNJA CO-PACK for ocular toxicities until improvement at the same or reduced dose. Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for any grade 4 toxicity.
Serious Skin Toxicities: Skin toxicities, including photosensitivity and severe cutaneous adverse reactions (SCARSs) occurred. Adhere to concomitant medications. Monitor for skin toxicities and interrupt, reduce or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity, tolerability and duration.
Hepatotoxicity: Monitor liver function tests prior to each cycle, on day 15 of the first 4 cycles, and as clinically indicated. Withhold, reduce or discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and persistence of abnormality.
Rhabdomyolysis: Monitor creatine phosphokinase prior to the start of each cycle, on day 15 of the first four cycles, and as clinically indicated. If increased CPK occurs, evaluate patients for rhabdomyolysis or other causes. Withhold, reduce or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and duration of the adverse reaction.
Embryo-Fetal Toxicity: AVMAPKI FAKZYNJA CO-PACK can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception.
Adverse Reactions
The most common (≥ 25%) adverse reactions, including laboratory abnormalities, were increased creatine phosphokinase, nausea, fatigue, increased aspartate aminotransferase, rash, diarrhea, musculoskeletal pain, edema, decreased hemoglobin, increased alanine aminotransferase, vomiting, increased blood bilirubin, increased triglycerides, decreased lymphocyte count, abdominal pain, dyspepsia, dermatitis acneiform, vitreoretinal disorders, increased alkaline phosphatase, stomatitis, pruritus, visual impairment, decreased platelet count, constipation, dry skin, dyspnea, cough, urinary tract infection, and decreased neutrophil count.
Drug Interactions
Strong and moderate CYP3A4 inhibitors: Avoid concomitant use with AVMAPKI FAKZYNJA CO-PACK.
Strong and moderate CYP3A4 inducers: Avoid concomitant use with AVMAPKI FAKZYNJA CO-PACK.
Warfarin: Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with warfarin and use an alternative to warfarin.
Gastric acid reducing agents: Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with proton pump inhibitors (PPIs) or H2 receptor antagonists. If use of an acid-reducing agent cannot be avoided, administer FAKZYNJA 2 hours before or 2 hours after the administration of a locally acting antacid.
Use in Specific Populations
Lactation: Advise not to breastfeed.
Fertility: May impair fertility in males and females.
Click here for full Prescribing Information.
About VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor
VS-7375 is a potential best-in-class, potent, and selective oral KRAS G12D dual ON/OFF inhibitor. VS-7375 is the lead program from the Verastem Oncology discovery and development collaboration with GenFleet Therapeutics. Verastem announced in April 2025 that the U.S. Investigational New Drug (IND) application for VS-7375 was cleared and plans to initiate a Phase 1/2a clinical trial in mid-2025. GenFleet's IND for VS-7375 (known as GFH375 in China) was approved in China in June 2024, and the first patient was dosed in a Phase 1/2 study in July 2024.
About the GenFleet Therapeutics Collaboration
The collaboration with GenFleet Therapeutics aims to advance three oncology discovery programs related to RAS/MAPK pathway-driven cancers. The collaboration provides Verastem with an exclusive option to obtain a license for each of the three compounds in the collaboration after the successful completion of pre-determined milestones in a Phase 1 trial. Verastem selected VS-7375 (also known as GFH375), an oral KRAS G12D (ON/OFF) inhibitor, as its lead program in December 2023 and the license for VS-7375 that was exercised in January 2025 is the first one from this collaboration. The licenses would give Verastem development and commercialization rights outside the GenFleet markets of mainland China, Hong Kong, Macau, and Taiwan.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI™ FAKZYNJA™ CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.
Forward-Looking Statements Notice
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as 'anticipate,' 'expect,' 'plan,' 'could,' 'may,' 'believe,' 'estimate,' 'forecast,' 'goal,' 'project,' and other words of similar meaning. Such forward-looking statements address various matters about, among other things, Verastem Oncology's programs and product candidates, strategy, future plans and prospects, including statements related to the potential for and timing of commercialization of product candidates, the anticipated timing for the initiation of the Phase 1/2a study for VS-7375/GFH375, the expected outcome and benefits of the Company's collaboration with GenFleet Therapeutics (Shanghai), Inc., the timing of commencing and completing trials and compiling data, the expected timing of the presentation of data by the Company and the potential clinical value of various of the Company's clinical trials. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others: the uncertainties inherent in research and development, such as the possibility of negative or unexpected results of clinical trials; that we may not see a return on investment on the payments we have and may continue to make pursuant to the collaboration and option agreement with GenFleet, or that GenFleet may fail to fully perform under the agreement; that we may not be successful in our launch or commercialization of AVMAPKI FAKZYNJA CO-PACK; that the development and commercialization of our product candidates may take longer or cost more than planned, including as a result of conducting additional studies or our decisions regarding execution of such commercialization; that data may not be available when expected; risks associated with preliminary and interim data, which may not be representative of more mature data; risks associated with the recent changes in administration policy or actions that may create regulatory uncertainty that may adversely affect our business; that our product candidates may not receive regulatory approval, become commercially successful products, or result in new treatment options being offered to patients; and the risks identified under the heading "Risk Factors" as detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (SEC) on March 20, 2025, as well as the other information we file with the SEC, are possibly realized. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this press release, and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Verastem Oncology
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
(unaudited)
Three months ended March 31,
2025
2024
Operating expenses:
Research and development
$
29,152
$
17,707
Selling, general and administrative
15,022
10,352
Total operating expenses
44,174
28,059
Loss from operations
(44,174
)
(28,059
)
Other expense
(40
)
(30
)
Interest income
960
1,367
Interest expense
(192
)
(1,130
)
Loss on debt extinguishment
(1,826
)

Change in fair value of preferred stock tranche liability

(6,011
)
Change in fair value of warrant liability
(2,416
)

Change in fair value of Notes
(4,415
)

Net loss
$
(52,103
)
$
(33,863
)
Net loss per share—basic and diluted
$
(0.96
)
$
(1.26
)
Weighted average common shares outstanding used in computing:
Net loss per share – basic and diluted
$
54,173
$
26,832
Expand
Verastem Oncology
Reconciliation of GAAP to Non-GAAP Financial Information
(in thousands, except per share amounts)
(unaudited)
Three months ended March 31,
2025
2024
Net loss reconciliation
Net loss (GAAP basis)
$
(52,103
)
$
(33,863
)
Adjust:
Stock-based compensation expense
1,788
1,483
Non-cash interest, net
30
(419
)
Change in fair value of preferred stock tranche liability

6,011
Loss on debt extinguishment
1,826

Change in fair value of warrant liability
2,416

Non-cash change in fair value of Notes
3,115

Severance and other

553
Adjusted net loss (non-GAAP basis)
$
(42,928
)
$
(26,235
)
Reconciliation of net loss per share
Net loss per share – diluted (GAAP Basis)
$
(0.96
)
$
(1.26
)
Adjust per diluted share:
Stock-based compensation expense
0.03
0.06
Non-cash interest, net

(0.02
)
Change in fair value of preferred stock tranche liability

0.22
Loss on debt extinguishment
0.05

Change in fair value of warrant liability
0.06

Non-cash change in fair value of Notes
0.03

Severance and other

0.02
Adjusted net loss per share – diluted
(non-GAAP basis)
$
(0.79
)
$
(0.98
)
Weighted average common shares outstanding used in computing net loss per share—diluted
$
54,173
$
26,832
Expand

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AI Time Platform Laurel Raises $100 Million to Transform the Professional Services Industry
AI Time Platform Laurel Raises $100 Million to Transform the Professional Services Industry

Business Wire

time17 minutes ago

  • Business Wire

AI Time Platform Laurel Raises $100 Million to Transform the Professional Services Industry

SAN FRANCISCO--(BUSINESS WIRE)--Laurel, the world's first AI Time platform, today announced it has raised $100 million in Series C funding led by IVP, with participation from GV (Google Ventures). Laurel will leverage this investment to scale its AI time platform and accelerate to solve what it calls the 'time intelligence challenge"—the inability for knowledge industries to accurately map time to business outcomes. In the age of AI, quantifying and understanding human capital goes from a 'nice to have' to a 'cannot exist without' for enterprises. In addition to IVP and GV, new investors in the round, which consists of primary and secondary funding, also include: 01.a (created by former CEO and COO of Twitter & CRO of Facebook), DST Global, Kevin Weil (CPO @ OpenAI), Alexis Ohanian, Vladimir Fedorov (CTO @ GitHub), Arash Ferdowsi (co-founder of Dropbox), and Hans Tung. These investors join returning investors ACME, Anthos, Gokul Rajaram, AIX Ventures, and Marc Benioff's TIME Ventures. The funding comes as Laurel experiences rapid adoption among enterprise professional services firms like Ernst & Young, Grant Thornton, Freshfields, and Crowell & Moring. Over the last 12 months, Laurel grew ARR +300% at double-digit scale, increased usage by +500%, and works with +100 of the top legal, accounting, and consulting firms across US, UK, EU, Australia, and Canada. Laurel's AI Time platform, now leveraged by hundreds of the world's top enterprise professional service firms, uses AI to automatically categorize, describe, and analyze how professionals spend their time on admin work. The platform's ability to connect time data with business outcomes has proven transformative for firms looking to maximize profits, allocate their resources effectively, and understand exactly what workflows to apply AI to and what agents to automate. Customers using the company's AI-native time platform report profit increases between 4-11%—driven by an additional 28 billable minutes per day per professional, and increased realization of 1-4%. Laurel's ROI methodology has been independently audited and validated by a Big-4 Firm. The platform currently processes over $5B in gross market value for its customers, and +$360M of that amount is net-new value attributable to Laurel. In addition, Laurel saves its professionals up to 80% in time recording, freeing them to work on high-leverage work. 'Laurel uniquely delivers value across lawyers, clients, finance, and marketing by streamlining time capture, enriching narratives, and accelerating accurate billing,' says Reed Cunningham, Chief Innovation Officer at global law firm Reed Smith. 'As firms assess the impact of AI and fixed fees, gaining granular intelligence with less effort is essential to redefining value within a firm and for its clients.' 'I've seen first-hand how Laurel can transform our approach to time intelligence. What used to be a manual process of time-keeping and entry is now significantly technology enabled,' says Matt Newnes, Partner and Tax Transformation leader at Ernst & Young. 'Laurel doesn't just help our people to capture time that they spend on work more comprehensively; it helps us to understand much more about how our teams work allowing us to identify best practices to help ensure we always drive the best outcomes for our clients. It has proven to be one of our most impactful AI investments, delivering measurable results while laying the foundation for broader transformation initiatives.' Automating time is Laurel's first step. Laurel's AI platform turns its proprietary data around work and time to address the #1 business problem impacting knowledge industries: operating without visibility into their supply chain. 'Nobody has ever mapped the input of time to the output of outcomes. Industries like legal and accounting are best at understanding their input (time), but still struggle to price value. On the flip side, industries like consulting and financial services understand value, but operate blind to the true cost of creation. While all other industries have been obsessed about optimizing their supply chain, the supply chain of knowledge work—which represents over 50% of Global GDP—has never been surfaced. This funding helps us solve this fundamental challenge while giving firms the data foundation they need to deploy AI strategically. We're not just automating time—we're creating the time intelligence layer that will transform how all knowledge industries operate," says Ryan Alshak, founder and CEO of Laurel. "Laurel has identified one of the largest efficiency gaps in the modern economy, one I understand deeply as a former CFO of a public company. Professional services represent trillions in global economic activity, yet these firms operate without basic visibility into their core resource – time. By solving the time intelligence challenge, Laurel creates a platform for broader AI transformation. As these industries invest heavily in AI over the next five years, Laurel's data foundation becomes essential infrastructure that truly tracks the ROI of AI. The market opportunity is massive, and Laurel's unique position makes them the clear leader in this space," says Ajay Vashee, General Partner at IVP. 'Laurel is creating the enterprise intelligence layer for knowledge work that leverages timekeeping as a product wedge,' said Frederique Dame, General Partner at GV. 'By capturing and organizing the full lifecycle of how professionals spend their time, Laurel unlocks a new class of data that makes work itself measurable, optimizable, and automatable. The goal isn't just better time tracking, it's building the data foundation for AI-powered workflows, predictive resourcing, and strategic insights.' Transforming How Knowledge Industries Understand and Optimize Work While manufacturing companies know exactly how much it costs to produce a car down to the penny, and retail businesses track inventory with precision, professional services firms have historically operated without understanding their most critical resource: human capital. Both the outcomes of the work itself and the time it takes to produce it. As a result, organizations are operating blind on what the biggest impact for AI is across their companies, and how to point people to highest value tasks (like Business Development, Relationship Management, and first principles strategic thinking). As knowledge industries plan to spend over $1 trillion on AI in the next five years, Laurel's time intelligence platform ensures these investments target the highest-impact opportunities. Key customer results include: Average recovery of 28+ billable minutes per professional per day 4-11% increase in overall firm profitability 80%+ reduction in time spent on manual time entry Real-time visibility into project profitability and resource utilization 'While Laurel is unique in that it is AI that generates profits, the reason everyone at Laurel cares so much about solving this problem is because people waste so much time at work, and the only way to solve this at scale is to deeply understand where that time is going,' says Alshak. 'And we're starting with professional services because that will give us the human-in-the-loop required to create the world's first-ever agentic timesheet. The average knowledge worker works 9 hours a day, but only adds leverage for 3. That is 3 hours a day we're doing work that should be done by agents, and 3 hours a day we're doing work that nobody should do. That is our opportunity set – 6.4 billion years currently being spent by knowledge workers on tasks humans no longer need to do. That is our opportunity.' About Laurel Laurel is the world's first AI Time platform for professional services firms. The company's AI transforms how organizations track, analyze, describe, and optimize their most valuable resource: time. By automating work time and connecting time data to business outcomes, Laurel enables firms to increase profitability, improve client delivery, and make data-driven strategic decisions. Founded in 2018, Laurel serves many of the world's largest accounting, consulting and law firms. For more information, visit About IVP IVP supercharges growth in breakout companies, converting momentum into market dominance. One of the original venture firms on Sand Hill Road, IVP partners with companies that define their eras—from Slack, Crowdstrike and Coinbase to Perplexity, Abridge, Glean and Chainguard—before the world truly appreciated them. Each year, IVP invests in just a dozen breakout founders ready to scale from millions to hundreds of millions in revenue and expand from one market to many. We've guided market leaders through cycles and storms, unlocking pivotal growth by activating the right expertise at the moments founders need it. With 130+ IPOs out of 400 investments, IVP helps ambitious founders defy limits, command industries and cement their place at the top.

Trump shouldn't import socialist price controls
Trump shouldn't import socialist price controls

The Hill

time32 minutes ago

  • The Hill

Trump shouldn't import socialist price controls

Remember when Republican presidential candidate Donald Trump castigated 'Comrade Kamala' Harris, then the Democratic nominee, for supporting price controls? It wasn't that long ago — just last August. At a campaign rally in Pennsylvania, Trump told the crowd: 'In her speech yesterday, Kamala went full Communist … She wants to destroy our country. After causing catastrophic inflation, Comrade Kamala announced that she wants to institute socialist price controls.' Harris's price controls were largely aimed at food in grocery stores, though she also frequently touted the 2022 Inflation Reduction Act's backdoor price controls — under the guise of 'negotiations' — on a certain number of expensive drugs. Trump was right to criticize Harris for supporting price controls on food, as well as prescription drugs. And, given the election results, it seems the public agreed with him. Price controls are the progressive left's go-to solution for almost all economic problems. But price controls virtually always lead to unintended consequences: shortages of the price-controlled products or services; lower quality as manufacturers cut corners to meet government-imposed price points; less innovation, since companies don't know if they'll be allowed to recover their costs; and a black market where people pay more to get what they want or need. So it's puzzling to see Trump now proposing a version of drug price controls himself. It's not the first time, either. During his first term, Trump pushed for 'drug importation,' encouraging U.S. citizens to buy medicines from countries like Canada — even though the FDA has warned those drugs could be fake or substandard. The effort fizzled, and even Florida, which tried a state-level importation scheme, eventually abandoned its program. Trump's latest idea is called 'Most Favored Nation' pricing. Details are thin, but a recent executive order says, 'To the extent consistent with law, the Secretary of Health and Human Services (Secretary) shall facilitate direct-to-consumer purchasing programs for pharmaceutical manufacturers that sell their products to American patients at the most-favored-nation price.' That 'most-favored' country will almost certainly be one with government-run health care — that is, socialized medicine. These systems are known for price controls, which lead to shortages, long wait times, and limited access to cutting-edge treatments. The goal of Most Favored Nation is to lower prices on expensive drugs. Americans do pay more for brand-name drugs than patients elsewhere. But they also pay less for generics, which account for roughly 90 percent of all prescriptions. One reason for the disparity is the middlemen in our system, known as pharmacy benefit managers. Their job is to negotiate lower prices with drugmakers. But those savings often don't make it to patients. Instead, pharmacy benefit managers keep a big chunk for themselves — on average, $0.42 of every $1 spent on brand-name drugs in the commercial market, by one estimate. In many cases, those pharmacy benefit manager cuts are larger than the total price of the drug in Europe. It's clear our system could work better. 'Shark Tank' entrepreneur Mark Cuban launched the Cost Plus Drug Company in 2022 to bypass these middlemen. The Cost Plus website says, 'Our prices are the true cost to get each medication from the manufacturer to you. We cut out the pharmacy middlemen and negotiate directly with manufacturers to get the best possible price.' The company tacks on 15 percent for overhead and a $5 filling fee. While customers may not save much on some widely used generics, the discounted prices on more expensive brand name and generic drugs are significantly lower than what most people would experience at their local pharmacy. Cost Plus has hundreds of drugs for nearly 100 listed medical conditions, and it's looking to add new drugs all the time. It's only been in business a few years and is working to expand. We also shouldn't ignore the fact that Americans are subsidizing below-market prices abroad. The United States funds a disproportionate share of global pharmaceutical innovation, while other wealthy nations impose price caps and benefit from our investment. If Trump wants to stop other countries from taking advantage of us, he should take the approach he's using to get countries to pay more for defense. Cuban's Cost Plus experiment proves we don't need Most Favored Nation pricing. Let socialized systems keep their socialized prices, limited access and denial of care. Tweaking a line Trump likes to use and applying it to prescription drugs: We don't need a new law. We just don't need a middleman. Merrill Matthews is a public policy and political analyst and the co-author of 'On the Edge: America Faces the Entitlements Cliff.'

DEEPX and Wind River Collaborate to Advance Mission-Critical Edge AI Applications
DEEPX and Wind River Collaborate to Advance Mission-Critical Edge AI Applications

Yahoo

time33 minutes ago

  • Yahoo

DEEPX and Wind River Collaborate to Advance Mission-Critical Edge AI Applications

SEOUL, South Korea & ALAMEDA, Calif., June 10, 2025--(BUSINESS WIRE)--DEEPX, a pioneering on-device AI semiconductor company, and Wind River, a global leader in delivering software for the intelligent edge, have collaborated on a hardware and software solution for next-generation edge AI. The partnership combines DEEPX's on-device AI semiconductors with Wind River's VxWorks® real-time operating system (RTOS) and Wind River® Helix™ Virtualization Platform to help advance solutions for mission-critical industries such as aerospace, defense, industrial, and robotics. "Edge AI is on a path to unlock incredible opportunities across a diverse range of industries. Together with Wind River's long heritage in software for markets that are highly dependent on safety, security, reliability, and edge expertise, DEEPX can provide customers with innovative edge AI platforms that deliver exceptional performance, cost, and power efficiency," said Lokwon Kim, CEO, DEEPX. "The growth of real-time physical AI is creating immense potential for mission-critical environments while also presenting new, complex challenges. The collaboration between DEEPX's advanced AI semiconductors and Wind River's proven edge technologies will help advance AI to deliver tremendous outcomes across applications and industries," said Avijit Sinha, Senior Vice President, Strategy and Global Business Development, Wind River. With the enablement of DEEPX's neural processing units (NPUs) on Wind River technologies, companies can easily add accelerated AI to their real-time or edge systems, at lower cost. DEEPX and Wind River work to deliver a pre-validated solution stack that addresses safety and security issues, helping companies significantly reduce complexity and development cycles. A leader in on-device AI, DEEPX develops advanced AI semiconductors that optimize performance, reduce power consumption, and enhance cost efficiency across various industries, including smart camera modules, smart mobility, smart factories, consumer electronics, smart cities, surveillance systems, and AI servers. DEEPX's cutting-edge AI chips are engineered for maximum efficiency and effortless integration into any device. Market-leading VxWorks is the industry's most trusted and widely deployed RTOS for mission-critical systems that must be secure and safe. The first commercial RTOS to support Open Container Initiative (OCI)–compliant containers, VxWorks enables companies to rapidly deploy new software-defined capabilities. Helix Platform is a hypervisor solution that enables engineering teams to consolidate multiple systems onto a single high-performance embedded system. It streamlines safety certification, reduces project risk, and accelerates time-to-market. About DEEPX DEEPX is leading the next-generation semiconductor market with its innovative AI technology and global competitiveness. The company has filed over 300 patents worldwide and registered more than 70, securing world-class proprietary AI semiconductor technology assets. DEEPX has been listed in the EE Times "Silicon 100" for two consecutive years and was named "Best Company in the AI Semiconductor Industry" by U.S. market research firm Frost & Sullivan. DEEPX continues solidifying its position as a key player in the AI semiconductor market through its global achievements and recognition for its innovation and technological leadership. About Wind River Wind River is a global leader in delivering software for the intelligent edge. For more than four decades, the company has been an innovator and pioneer, powering billions of devices and systems that require the highest levels of security, safety, and reliability. Wind River software and expertise are accelerating digital transformation across industries including automotive, aerospace, defense, industrial, medical, and telecommunications. The company offers a comprehensive portfolio supported by world-class global professional services and support and a broad partner ecosystem. To learn more, visit Wind River at Wind River is a trademark or registered trademark of Wind River Systems, Inc., and its affiliates. Other names may be the trademarks of their respective owners. View source version on Contacts MEDIA CONTACT Jenny SuhWind

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store